Clinical trial NCT02871492: Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Official title: A Randomized, Double-blind, Multi-center, Three Arm (Pritelivir, Placebo and Zovirax®) Parallel Group, Comparative Trial to Assess the Efficacy and Safety of Pritelivir 5% w/w Ointment for the Treatment of Recurrent Herpes Labialis in Adults - LipP1
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Herpes Labialis
Keywords: HSV, pritelivir, herpes, herpes labialis, topical,
Lead sponsor: AiCuris Anti-infective Cures AG
Sponsor class: INDUSTRY
Collaborators: name: Novella Clinical
First posted: 2016-08-18
Enrollment: 362
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The start of treatment with trial medication will be initiated by the subject within one hour of noticing the first sign or symptom (eg, prodrome) of a recurrence of herpes labialis. Trial medication will be applied to the affected area 5 times daily for 4 days.

After self-initiation of treatment with trial medication subjects will be assessed daily by the Investigator until complete healing for a maximum of 13 days.

Subjects will document application of trial medication and the status of their lesion in a diary. There will also be blood sampling, ECG measurement and physical examination performed at the investigational site.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women of any ethnic group aged ≥18 years ;
* Subjects should have experienced ≥4 recurrences of herpes labialis in the previous 12-months period;
* Subjects should have experienced prodromal symptoms in at least 50% of recurrent Herpes labialis (rHL) episodes and should have developed ulcerative lesions that have progressed through vesicle, ulcer, and crust stages in at least 50% of the episodes;
* Willingness not to use any topical application (such as cosmetics, lip balm, sunscreens etc...) other than the trial medication in the area of lesion development from start of prodromal symptoms to complete healing;
* Willingness not to use any systemic and topical anti-Herpes Simplex Virus (HSV) agent during the trial participation including prescription and over-the-counter (OTC) products;
* Willingness not to use any systemic, anti-inflammatory or analgesic agents from start of prodromal symptoms to healing;
* Willingness to refrain from mechanical disruption (ie, scrubbing, lancing, shaving) of the prodromal area or lesion after start of treatment with trial medication until end of the trial participation;
* Women of child bearing potential and males must use adequate contraception;
* Subject must give written informed consent.
* Subjects with current lesion may be enrolled, but they must not treat the lesion present at screening/randomization with the trial medication; they should be instructed to wait for their next subsequent lesion

Exclusion Criteria:

* Known intolerance to pritelivir or any of the ointment ingredients;
* Known intolerance to Zovirax® Cream or any of the ingredients (ie, acyclovir, cetostearyl alcohol, mineral oil, poloxamer 407, propylene glycol, sodium lauryl sulfate, and white petrolatum) or valacyclovir;
* Any skin conditions that could interfere with the assessment of herpes labialis recurrences (eg, eczema, psoriasis, acne etc...)
* Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial
* Pregnant and/or breastfeeding women
* Participation in any investigational drug trial within the last 30 days before randomization for this clinical trial
* Previous treatment with pritelivir tablets
* Previous participation in a HSV vaccination Trial unless having received placebo.
* Clinically relevant ECG abnormalities (eg, QTc according to Fridericia: QTcF \> 450 ms for males and QTcF \> 470 ms for females; PR \> 220 ms) at screening.
* Clinically relevant abnormalities in laboratory indices at screening which in the opinion of the investigator might have an impact on the safety and evaluability of the subject.
* Known chronic infections which in the opinion of the investigator might have an impact on the safety and evaluability of the subject.
* Evidence of active malignancy or immunodeficiency disease, or require chronic use of immunosuppressive drugs (eg, systemic steroids) or topical steroids, or chronically use antiviral medication with activity against HSV.
* HIV positive based on screening labs.

Primary outcomes:
measure: Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment
timeFrame: 13 days
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
state: Arizona
city: Santa Rosa
country: United States
state: California
city: Pinellas Park
country: United States
state: Florida
city: Edina
country: United States
state: Minnesota
city: Saint Louis
country: United States
state: Missouri
city: Akron
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Anderson
country: United States
state: South Carolina
city: Greer
country: United States
state: South Carolina
city: San Antonio
country: United States
state: Texas
Study officials:
References: